封面
市場調查報告書
商品編碼
1612269

動脈粥狀硬化藥物市場:按藥物類別、給藥途徑、階段、分銷管道分類 - 全球預測 2025-2030

Atherosclerosis Drugs Market by Drug Class (Anti-Hypertensive Drugs, Antiplatelet Agents, Cholesterol-lowering Drugs), Route of Administration (Injectable, Oral), Disease Stage, Distribution Channel - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年動脈粥狀硬化藥物市值為225.9億美元,預計到2024年將達到238.2億美元,複合年成長率為5.66%,預計到2030年將達到332.3億美元。

動脈粥狀硬化藥物涵蓋多種藥物干預措施,旨在預防和治療動脈壁上的斑塊積聚,從而導致心臟病和中風等心血管疾病。其中包括降血脂藥物,如他汀類藥物、PCSK9抑制劑、膽固醇吸收抑制劑,以及新藥,如反義寡核苷酸和基於RNA的治療藥物。由於人口老化和不良飲食習慣和缺乏運動等生活方式紊亂,全世界心血管疾病的發病率不斷增加,這一事實清楚地表明了對這些藥物的需求。這些藥物主要用於臨床環境,並開給有動脈粥狀硬化風險或被診斷出患有動脈粥狀硬化的患者。最終用途包括醫院、專科診所和提供遠端病患管理的遠端醫療平台。

主要市場統計
基準年[2023] 225.9億美元
預計年份 [2024] 238.2億美元
預測年份 [2030] 332.3億美元
複合年成長率(%) 5.66%

市場成長受到藥物開發技術進步、醫療保健支出增加、心血管健康意識增強以及藥物創新有利法規等因素的影響。此外,生技公司和研究機構之間的夥伴關係和合作也提供了巨大的機會。由於醫療基礎設施的改善和患者數量的增加,亞太地區等新興市場正在展現出希望。然而,市場開拓面臨藥物開發成本高、監管要求嚴格以及影響患者依從性的副作用風險等挑戰。專注於個人化醫療、基因編輯技術和聯合治療的創新和研究提供了巨大的成長機會。追求不僅能降低膽固醇,還能解決發炎和動脈粥狀硬化的其他根本原因的治療方法是一個成熟的發展領域。

市場競爭非常激烈,因此從戰略上講,我們需要專注於地域擴張,特別是在新興國家,並投資研發以保持領先地位。透過開拓夥伴關係關係並利用人工智慧和機器學習進行藥物開發和分銷的預測分析來增強您的市場地位。為了解決這些限制,公司應專注於克服監管障礙,與政策制定者合作,簡化核准流程,更快地將新藥推向市場。

市場動態:揭示快速發展的動脈粥狀硬化藥物市場的關鍵市場洞察

由於供需的動態交互作用,動脈粥狀硬化藥物市場正在經歷轉型。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 心血管疾病和動脈粥狀硬化疾病的盛行率增加
    • 努力促進心臟病的診斷和早期治療
  • 市場限制因素
    • 召回動脈硬化治療藥物的風險
  • 市場機會
    • 正在進行的研究計劃旨在引進先進的動脈硬化治療方法
    • 政府對動脈粥狀硬化藥物的核准增加
  • 市場挑戰
    • 新開發的併發症

波特五力:駕馭動脈粥狀硬化藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解外部對動脈硬化治療藥物市場的影響

外部宏觀環境因素在塑造動脈粥狀硬化藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並幫助他們做出積極主動的決策。

市場佔有率分析 了解動脈硬化治療藥物市場的競爭狀況

對動脈粥狀硬化藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣動脈粥狀硬化治療市場供應商績效評估

FPNV定位矩陣是評估動脈粥狀硬化藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商,從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商,並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議,描繪動脈粥狀硬化藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說,動脈粥狀硬化藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機,並取得長期成功。

本報告對市場進行了全面分析,涵蓋關鍵重點領域:

1. 市場滲透率:對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:徹底分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病和動脈粥狀硬化疾病的盛行率增加
      • 努力促進心臟病的診斷和早期治療
    • 抑制因素
      • 動脈硬化治療藥物回想風險
    • 機會
      • 正在進行的研究計劃引進先進的動脈粥狀硬化藥物
      • 政府對動脈粥狀硬化藥物的核准增加
    • 任務
      • 動脈硬化開發新藥的併發症
  • 市場區隔分析
    • 藥物類別: 降膽固醇藥物治療普通動脈硬化採用率高
    • 分銷管道:透過線上管道可得性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的動脈硬化治療藥物市場

  • 抗高血壓藥
  • 抗血小板藥
  • 降低膽固醇藥物

第7章動脈硬化治療藥物市場:依給藥途徑

  • 可注射的
  • 口服

第8章依疾病階段分類的動脈硬化治療藥物市場

  • 動脈粥狀硬化形成
  • 動脈粥狀硬化斑塊的形成
  • 脂肪紋的形成

第9章動脈硬化治療藥物市場:依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 北美和南美動脈粥狀硬化治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區動脈硬化治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲動脈粥狀硬化治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
    • 美國國立衛生研究院 (NIH) 向德克薩斯心臟研究所撥款 114 萬美元,用於開發新藥
    • 美國FDA核准諾華 Rekvio (inclisiran) 的適應症擴大至高 LDL 膽固醇水平的成人
    • FDA核准治療心血管疾病的發炎藥
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Agepha Pharma US
  • Amgen Inc.
  • Anthos Therapeutics
  • Artery Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cardurion Pharmaceuticals
  • CSL Behring
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • NewAmsterdam Pharma
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Verve Therapeutics
Product Code: MRR-F97DD5A7DBFE

The Atherosclerosis Drugs Market was valued at USD 22.59 billion in 2023, expected to reach USD 23.82 billion in 2024, and is projected to grow at a CAGR of 5.66%, to USD 33.23 billion by 2030.

Atherosclerosis drugs encompass a wide range of pharmaceutical interventions aimed at preventing and treating the buildup of plaque in arterial walls, which can lead to cardiovascular diseases such as heart attack and stroke. The scope includes lipid-lowering agents like statins, PCSK9 inhibitors, cholesterol absorption inhibitors, and emerging new classes such as antisense oligonucleotides and RNA-based therapies. The necessity for these drugs is underscored by the rising incidence of cardiovascular diseases globally, driven by aging populations and lifestyle factors like poor diet and lack of exercise. These pharmaceuticals find applications primarily in clinical settings, prescribed for patients at risk of or diagnosed with atherosclerosis, with additional potential in preventive healthcare. End-use scope encompasses hospitals, specialty clinics, and increasingly telemedicine platforms offering remote patient management.

KEY MARKET STATISTICS
Base Year [2023] USD 22.59 billion
Estimated Year [2024] USD 23.82 billion
Forecast Year [2030] USD 33.23 billion
CAGR (%) 5.66%

Market growth is influenced by factors such as technological advancements in drug development, increased healthcare expenditure, heightened awareness of cardiovascular health, and favorable regulations for drug innovations. Additionally, partnerships and collaborations between biotech firms and research institutions present significant opportunities. Emerging markets like Asia-Pacific show promise with improving healthcare infrastructures and rising patient populations. However, market growth faces challenges such as high drug development costs, stringent regulatory requirements, and the risk of adverse drug reactions impacting patient compliance. Innovation and research focusing on personalized medicine, gene editing technologies, and combination therapy offer substantial growth opportunities. The pursuit of therapies that not only lower cholesterol but also address inflammation and other underlying causes of atherosclerosis is an area ripe for development.

The competitive nature of the market necessitates a strategic focus on geographic expansion, especially into emerging economies, and investment in R&D to stay ahead. Cultivating partnerships and leveraging AI and machine learning for predictive analytics in drug development and distribution can enhance market positioning. Addressing limitations, firms should focus on overcoming regulatory hurdles by engaging with policymakers to streamline approval processes, thus accelerating time-to-market for new therapies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atherosclerosis Drugs Market

The Atherosclerosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of CVDs and atherosclerosis diseases
    • Initiatives promoting diagnosis and early treatment of heart diseases
  • Market Restraints
    • Risk of recalls of atherosclerosis drugs
  • Market Opportunities
    • Ongoing research projects for introducing advanced atherosclerosis drugs
    • Rising government approvals for atherosclerosis drugs
  • Market Challenges
    • Complications of new atherosclerosis drug development

Porter's Five Forces: A Strategic Tool for Navigating the Atherosclerosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atherosclerosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atherosclerosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atherosclerosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atherosclerosis Drugs Market

A detailed market share analysis in the Atherosclerosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atherosclerosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atherosclerosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atherosclerosis Drugs Market

A strategic analysis of the Atherosclerosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atherosclerosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agepha Pharma US, Amgen Inc., Anthos Therapeutics, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cardurion Pharmaceuticals, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., NewAmsterdam Pharma, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, and Verve Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Atherosclerosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-Hypertensive Drugs, Antiplatelet Agents, and Cholesterol-lowering Drugs.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Disease Stage, market is studied across Atheroma Formation, Atherosclerotic Plaques Formation, and Fatty Streaks Formation.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of CVDs and atherosclerosis diseases
      • 5.1.1.2. Initiatives promoting diagnosis and early treatment of heart diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of recalls of atherosclerosis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research projects for introducing advanced atherosclerosis drugs
      • 5.1.3.2. Rising government approvals for atherosclerosis drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complications of new atherosclerosis drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment
    • 5.2.2. Distribution Channel: Improved availability of atherosclerosis drugs through online channels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Atherosclerosis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Hypertensive Drugs
  • 6.3. Antiplatelet Agents
  • 6.4. Cholesterol-lowering Drugs

7. Atherosclerosis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Atherosclerosis Drugs Market, by Disease Stage

  • 8.1. Introduction
  • 8.2. Atheroma Formation
  • 8.3. Atherosclerotic Plaques Formation
  • 8.4. Fatty Streaks Formation

9. Atherosclerosis Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Atherosclerosis Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Atherosclerosis Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Atherosclerosis Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. NIH Awards The Texas Heart Institute USD 1.14 Million To Develop A Novel Drug For Atherosclerotic Cardiovascular Disease
    • 13.3.2. US FDA Approves Expanded Indication For Novartis Leqvio (inclisiran) For Adults With High LDL-C
    • 13.3.3. Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agepha Pharma US
  • 3. Amgen Inc.
  • 4. Anthos Therapeutics
  • 5. Artery Therapeutics, Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. Cardurion Pharmaceuticals
  • 10. CSL Behring
  • 11. Eli Lilly and Company
  • 12. Esperion Therapeutics, Inc.
  • 13. NewAmsterdam Pharma
  • 14. Novartis AG
  • 15. Novo Nordisk A/S
  • 16. Pfizer Inc.
  • 17. Regeneron Pharmaceuticals, Inc.
  • 18. Sanofi SA
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Verve Therapeutics

LIST OF FIGURES

  • FIGURE 1. ATHEROSCLEROSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ATHEROSCLEROSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ATHEROSCLEROSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROMA FORMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROSCLEROTIC PLAQUES FORMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FATTY STREAKS FORMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023